New treatment options for MBC
Although metastatic breast cancer isn’t curable, it is treatable. The goal of treatment is to keep the cancer under control while reducing symptoms and side effects so you can have the best possible quality of life.
There are many different kinds of treatments available for metastatic breast cancer, including:
Research is changing the treatment of metastatic breast cancer. It may be surprising to learn that most people starting treatment for metastatic breast cancer do not begin with chemotherapy. Many people start with hormonal therapy or targeted therapy.
Among the newer metastatic breast cancer treatments that have been developed because of research are these targeted therapies:
- PARP inhibitors: These medicines cause cancer cells to die by preventing them from fixing damaged DNA. PARP inhibitors are approved to treat metastatic breast cancer in people who have an inherited BRCA1 or BRCA2 genetic mutation.
- PIKC3A inhibitors: These treatments are approved to treat certain metastatic breast cancers whose tumor cells have a mutation in the PIK3CA gene. PIKC3A inhibitors disrupt the activity of an enzyme called P13 kinase, interfering with cancer cells’ ability to grow.
- Trop-2 antibody-drug conjugates: This drug combination targets a protein called Trop-2, often found in triple-negative breast cancers. These treatments combine the Trop-2 antibody and a chemotherapy drug so that chemotherapy can be delivered directly to certain cancer cells.
These are just a few examples. You and your healthcare team can work together to create a tailored treatment plan for you. If the cancer’s response to treatment changes over time, your plan can be adjusted to help ensure you’re continuing to receive the most effective treatment. And any time you’re considering a treatment is a good time to ask your doctor about opportunities to participate in a clinical trial. Clinical trials provide access to treatments that may be very effective but are not yet FDA-approved.
“I think the most exciting aspect of metastatic breast cancer management for the near and mildly distant future is the further refinement of genomically driven treatment,” says Pallav Mehta, MD. “Breast cancers, like most solid tumors, often have several driver mutations and continue to acquire new mutations as the cancer progresses. We're getting better not just at identifying these mutations, but also at understanding what these aberrant genes actually do to the cell. And we’re getting better at designing drugs that can target the protein product of these genes.
“A second exciting advance is in the field of immunotherapy, which is a way to have the patient's own immune system wake up from the stupor induced by the cancer and do its job, which is to protect the house,” says Dr. Mehta. “CAR T-cell therapy [immunotherapy that alters a person’s immune cells to target cancer] is exciting, checkpoint inhibitors are showing some promise, and even vaccines have relevance again.”
Learn more about treatment options and read the latest treatment news.